Reply by the Authors

We thank Zou et al for their interest in and comments on our paper entitled “XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis.” Accordingly, we made the following responses. Re: Li et al.: XRCC3 T241M Polymorphism and Bladder Cancer Risk: A Meta-analysis (Urology 2010;77:511)UrologyVol. 77Issue 3PreviewWe read with great interest the recent paper by Li et al.1 They performed a meta-analysis of 16 case-control studies (5298 cases and 6614 controls) to evaluate the role of the X-ray repair cross complementing group 3 (XRCC3) T241M polymorphism in bladder cancer susceptibility. The results of the meta-analysis suggest an increased risk role of XRCC3 241 MM genotype in bladder cancer among all subjects. Nevertheless, several issues seem worth comment. Full-Text PDF